## EXPRESS MAIL NO. EV 913 329 700 US



## UNITED STATES PATENT AND TRADEMARK OFFICE

Zeligs.

Confirmation No.:

8529

APP

10/774,324

Art Unit:

1617

February 6, 2004

Examiner:

Wang, Shengjun

BINED USE OF CRUCIFEROUS OLES AND CHELATORS FOR THE EATMENT OF PAPILLOMAVIRUS-

LATED CONDITIONS

Attorney Docket No.: 9439-013-999

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references A01-A13, B01 and C01-C26 which are listed on the attached List of References Cited by Applicant. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and published U.S. application (i.e., references A01-A13) are not submitted herewith. Copies of references B01 and C01-C26 are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: August 1, 2007

<u> 29,258</u>

(Reg. No.)

Thomas E. Friebel

JONES DAY 222 E. 41<sup>st</sup> Street

New York, New York 10017

(212) 326-3939

Express Mail No.: <u>EV 913 329 700 US</u>

Sheet 1 of 2

	ATTY. DOCKET NO.	APPLICATION NO.		
	9439-013-999	10/774,324		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT			
	Zeligs M.			
DIPE	FILING DATE	ART UNIT		
The state of the s	February 6, 2004	1617		
110 . 4				

AUG o 1 7	U.S. PATENT DOCUMENTS				
*Examinetration	Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
A01	5,767,135	06/16/98	Fernandez-Pol		
A02	5,948,808	09/07/99	Safe		
A03	6,001,868	12/14/99	Firestone et al.		
A04	6,242,492	06/05/01	Bergeron, Jr.		
A05	6,335,443	01/01/02	Geraci et al.		
A06	6,399,645	06/04/02	Bell et. al.		
A07	6,406,706	06/18/02	Haque et al.		
A08	6,410,570	06/25/02	Fernandez-Pol		
A09	6,432,926	08/13/02	Howley et al.		
A10	6,468,557	10/22/02	Lezdey et al.		
A11	2003-0096855	05/22/03	Zeligs		
A12	2004-0013965	03/04/04	Jong et. al.		
A13	2005-0063903	03/24/05	Zeligs		

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т
	B01	WO 01/24799	04/12/01	Bernstein		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author, title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	Т
	C01	Apseloff G, Therapeutic uses of gallium nitrate: past, present, and future. Am J Ther. 1999 November;6(6):327-39.	
	C02	Bell M C, Crowley-Nowick P, Bradlow H L, Sepkovic D W, Schmidt-Grimminger D, Howell P, Mayeaux E J, Tucker A, Turbat-Herrera E A and Mathis J M, Placebo-controlled trial of indole-3-carbinol in the treatment of CIN, Gynecol Oncol. 2000 August;78(2):123-9.	
	C03	Bradfield C A and Bjeldanes L F, Structure-activity relationships of dietary indoles: a proposed mechanism of action as modifiers of xenobiotic metabolism. J Toxicol Environ Health. 1987;21(3):311-23.	
	C04	Chen D Z, Qi M, Auborn K J and Carter T H, Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J Nutr. 2001 December;131(12):3294-302.	
<u></u>	C05	Chen I et al., Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of Diindolylmethane. Carcinogenesis 1998, 19(9):1631-9.	

 <b>EXAMINER</b> NYI-3994892v1	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EV 913 329 700 US Sheet 2 of 3

		Silect 2 of 5
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9439-013-999	APPLICATION NO. 10/774,324
	APPLICANT Zeligs M.	
FF E AND W	FILING DATE February 6, 2004	ART UNIT 1617
1,1601		

A		[t]	
Examiner August 184	OF MARK	NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	Т
	C06	Chinni S R, Li Y, Upadhyay S, Koppolu P K and Sarkar F H, Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 2001 May 24;20(23):2927-36.	
	C07	Dashwood R H, Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables? Chem Biol Interact, 1998 Mar 12, 110(1-2):1-5.	
	C08	De Kruif Calif., Marsman J W, Venekamp J C et al., Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interact 1991; 80(3):303-15.	
	C09	Fernandez-Pol J A, Klos D J and Hamilton P D, Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. Anticancer Res. 2001  November-December:21(6A):3773-6.	
	C10	Fukuchi K, Tomoyasu S, Tsuruoka N and Gomi K, Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett. 1994 Aug. 15;350(1):139-42.	
	C11	Gao J and Richardson D R, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood. 2001 Aug. 1;98(3):842-50.	
	C12	Gao X, Petroff B K, Oluola O, Georg G, Terranova P F and Rozman K K, Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation. Toxicol Appl Pharmacol. 2002 Sep. 15;183(3):179-88.	
	C13	Gillison M L and Shah K V, Human papillomavirus-associat- ed head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol. 2001 May;13(3):183-8.	
	C14	Harwood C A and Proby C M, Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis. 2002 April;15(2):101-14.	
	C15	Hasegawa M, Ohoka I, Yamazaki K, Hanami K, Sugano I, Nagao T, Asoh A, Wada N, Nagao K and Ishida Y, Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection. Pathol Int. 2002 July:52(7):442-50.	
	C16	Hong C, Firestone G L and Bjeldanes L F, Bc1-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells. Biochem Pharmacol. 2002 Mar. 15;63(6):1085-97.	
	C17	Jin L. et al., Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice, Cancer Res. 1999, 59(16):3991-7.	
	C18	Marks P A, Richon V M and Rifkind R A, Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000 Aug. 2; 92(15):1210-6.	
	C19	Romeo A M, Christen L, Niles E G and Kosman D J, Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J. Biol. Chem. 2001 Jun. 29;276(26):24301-8.	
	C20	Rosen, C.A., Woodson, G. E. et al., Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngology Head Neck Surgery 1998, 118:810-5.	
	C21	Serth J, Panitz F, Paeslack U, Kuczyk M A and Jonas U, Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res. 1999 Feb. 15; 59(4): 823-5.	_
	C22	Simonart T, Boelaert J R, Andrei G, van den Oord J J, Degraef C, Hermans P, Noel J C, Van Vooren J P, Heenen M, De Clercq E and Snoeck R, Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model. Int J Cancer 2002 Jul. 10;100(2):140-3.	
	C23	Simonart, et al., Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells.  Gynecologic Oncology, 2002, Vol. 85, 94-102	

EXAMINER NYI-3994892v1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformat considered. Include copy of this form with next communication to applicant.	nce with MPEP 609; Draw line through citation if not in conformance and not

t with

Express Mail No.: <u>EV 913 329 700 US</u>

Sheet 3 of 3

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9439-013-999	APPLICATION NO. 10/774,324
	APPLICANT Zeligs M.	
	FILING DATE February 6, 2004	art unit 1617

E SUA	. 6	NON PATENT LITERATURE DOCUMENTS	
Examiner & Initials	TRAD	(Include name of the author, title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	Т
	C24	Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T, Kato H, Furugen Y, Yoshida K, Kato K and Wake N, Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer 2001 Oct. 15; 94(2): 257-67.	
	C25	Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A, Shah K V, Snijders P J, Peto J, Meijer C J and Munoz N, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 September; 189(1):12-9.	
	C26	Zambrano A, Kalantari M, Simoneau A, Jensen J L, Villarreal L P, Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002 Dec. 1;53(4):263-76.	

<b>EXAMINER</b>	
NVI-3094892v1	